Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L36a pseudogene 20 (RPL36AP20) is one of multiple processed pseudogenes of the ribosomal protein L36a gene (RPL36A) dispersed throughout the human genome[9][3]. Pseudogenes are typically non-functional genomic sequences that arise from duplication or retrotransposition events and do not encode active proteins, nor do they participate in canonical molecular or cellular functions. RPL36AP20 does not act as a receptor, enzyme, transporter, transcription factor, or any functional molecular target and cannot be modulated by small molecules, biologics, or other drugs. In contrast, its parent gene, ribosomal protein L36a (RPL36A), encodes a constituent protein of the cytoplasmic 60S ribosomal subunit and is involved in protein synthesis, with possible relevance in cancer biology[1][7][4]. However, RPL36AP20 itself has no known functional or therapeutic relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L36a pseudogene 20 (RPL36AP20).